Orient Pharma Co., Ltd.

Quick facts

Phase 3 pipeline

• 1PC002 · Oncology
  This drug is a small molecule that targets the PI3K/AKT/mTOR pathway.
• 1PC111 · Oncology
  This drug is a small molecule that targets the PI3K/AKT pathway.
• ORADUR®-Methylphenidate · Neurology / Psychiatry
  ORADUR-Methylphenidate is an extended-release formulation of methylphenidate that inhibits the reuptake of dopamine and norepinephrine in the central nervous system.
• Placebo First, then ORADUR® · Pain management
  ORADUR is a sustained-release formulation of buprenorphine.

Phase 2 pipeline

• Isoniazid with HUEXC030 and RZE

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Orient Pharma Co., Ltd. portfolio CI brief
• Orient Pharma Co., Ltd. pipeline updates RSS